文献速递冠心病血脂与心血管预防

秋水仙碱与克隆性造血纵向动态:LoDoCo2试验探索性亚研究

Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-08-29

该研究为LoDoCo2试验的探索性亚研究,纳入854例慢性冠心病患者,在4个时间点进行高覆盖靶向测序检测克隆性造血驱动突变及变异等位基因频率。随机分配至安慰剂组与克隆性造血克隆年增长14.9%相关,秋水仙碱组增长6.3%但未达统计学显著差异;在TET2克隆性造血中,秋水仙碱与克隆生长减弱相关。

要点

  • 秋水仙碱与TET2克隆性造血克隆生长减弱相关,交互P=0.04。
  • 安慰剂组克隆年均增长14.9%,秋水仙碱组6.3%,组间差异未达统计学显著。
  • 非DNMT3A克隆性造血者中,秋水仙碱组1年白介素-6增幅小于安慰剂组。

核心结论

  • 低剂量秋水仙碱治疗与TET2克隆性造血克隆扩增减弱相关,提示其可能抑制关键驱动突变的增殖优势并减轻相关心血管风险。

研究设计与样本

  • LoDoCo2试验的探索性亚研究,纳入854例慢性冠心病患者,共2,047次观察,覆盖基线、30天开放标签秋水仙碱0.5 mg每日导入期后、随机后1年及研究结束时(中位随访25.0个月)4个时间点。
  • 采用高覆盖靶向测序检测克隆性造血驱动突变并量化变异等位基因频率,用广义线性混合模型评估克隆动态。

主要发现

  • 随机分配至安慰剂与克隆性造血克隆大小年增长14.9%相关(βtime=0.14;95%CI:0.08至0.21),秋水仙碱组年增长6.3%但无统计学意义(βtime=0.06;95%CI:-0.01至0.14),组间差异未达统计学显著(Pinteraction=0.13)。
  • 在TET2克隆性造血中,秋水仙碱组克隆生长减弱(βtime=0.09;95%CI:-0.04至0.22),安慰剂组为(βtime=0.27;95%CI:0.16至0.37),Pinteraction=0.04。
  • 在非DNMT3A克隆性造血个体中,秋水仙碱组1年内白介素-6水平增幅小于安慰剂组(分别增加30.0%与98.1%;Pinteraction=0.01)。

临床怎么用

  • 对于慢性冠心病合并TET2克隆性造血的患者,低剂量秋水仙碱可能减弱克隆扩增,但需前瞻性研究验证后方可指导临床决策。

局限性

  • 本研究为探索性亚研究,组间克隆增长差异未达统计学显著,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clonal hematopoiesis (CH) is an aging-related hematologic condition associated with increased risk for cardiovascular events. Larger CH clones associate more strongly with cardiovascular risk. Preclinical data indicate that inflammatory signaling drives expansion of CH clones and CH-associated cardiovascular disease. However, the effect of anti-inflammatory therapies on CH clonal dynamics in humans is unclear. OBJECTIVES: The goal of this study was to test the association of randomization to colchicine vs placebo with CH growth in participants with chronic coronary artery disease. It also assessed the association of colchicine use with change in inflammatory biomarkers over time according to CH status. METHODS: In this exploratory substudy of the LoDoCo2 (Low-Dose Colchicine 2) trial, high-coverage targeted sequencing was used to detect CH driver mutations and to quantify variant allele frequency at 4 timepoints: baseline, after a 30-day open-label colchicine run-in phase (0.5 mg daily), 1 year postrandomization to colchicine or placebo, and at end of study (median follow-up of 25.0 months). Clonal dynamics were assessed by using a generalized linear mixed model. High-sensitivity C-reactive protein and interleukin-6 were additionally measured at baseline, randomization, and 1 year postrandomization. RESULTS: In total, 854 participants contributed 2,047 observations across 4 timepoints, including before and after the prerandomization colchicine run-in period. Randomization to placebo was associated with a 14.9% annual increase in CH clone size (βtime = 0.14; 95% CI: 0.08 to 0.21) vs a nonsignificant 6.3% increase with colchicine (βtime on colchicine: 0.06; 95% CI: -0.01 to 0.14), although this difference between treatment arms was not statistically significant (Pinteraction = 0.13). Compared with placebo, colchicine was associated with attenuated clonal growth in TET2 CH (βtime on colchicine: 0.09 [95% CI: -0.04 to 0.22]; βtime placebo: 0.27 [95% CI: 0.16 to 0.37]; Pinteraction= 0.04). Among individuals with non-DNMT3A CH, interleukin-6 levels increased to a lesser extent in those receiving colchicine vs placebo over 1 year (30.0% vs 98.1% increase, respectively; Pinteraction = 0.01). CONCLUSIONS: In this exploratory analysis, treatment with low-dose colchicine was associated with attenuated clonal expansion in TET2 CH. These findings suggest the potential for colchicine to curb the proliferative advantage of key CH driver mutations and to mitigate their associated risk of cardiovascular disease. Further validation in prospective studies is warranted.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mohammadnia N, Xue L, Vestjens LTW, et al. Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial. J Am Coll Cardiol. 2025. PMID: 40892620. doi:10.1016/j.jacc.2025.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。